Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Advanced or metastatic solid tumor with an activating PIK3CA mutation.
Refractory to or intolerant of available therapies
Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in blood.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

SNV4818 in Participants With Advanced Solid Tumors